The dynamics of relapses during treatment switch in relapsing-remitting multiple sclerosis

被引:3
|
作者
Frascoli, Federico [1 ]
Roos, Izanne [2 ,3 ]
Malpas, Charles B. [2 ,3 ]
Kalincik, Tomas [2 ,3 ]
机构
[1] Swinburne Univ Technol, Dept Math, Fac Sci Comp & Engn Technol, Melbourne, Vic, Australia
[2] Univ Melbourne, Dept Med, CORe, Melbourne, Vic 3050, Australia
[3] Royal Melbourne Hosp, Melbourne MS Ctr, Dept Neurol, Melbourne, Vic 3050, Australia
基金
澳大利亚研究理事会; 英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词
Population models; Multiple sclerosis; Drug trials; MATHEMATICAL-MODEL; ASSOCIATION; THERAPY; MRI;
D O I
10.1016/j.jtbi.2022.111091
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Based on reported trends in relapse incidence among patients with relapsing-remitting multiple sclerosis, an original model for the response to disease modifying therapies is proposed. With a population approach and separate states for patients accounting for their risk of relapses, a system of nonlinear equations is formulated, similarly to established epidemiological models. Different parameters describe the effect of drugs and treatment switch in reducing the frequency of relapses. The model allows for a good fit to previously published data for experiments where different drugs are used. It also shows that different treatments maintain a high degree of similarity, with analogous dynamical features: a pre-treatment increment in relapse frequency leading to a distinct peak, a rapid drop after treatment switch and a plateau corresponding to a new base relapse activity, which seems dependant on the treatment chosen. A sensitivity analysis shows that the uncertainty in the initial proportions of different populations and the frequency of relapses can modify the overall dynamics of the response to treatment. Drugs are observed to induce effects that depend on patient sample's intrinsic characteristics, producing two clearly distinct and independent dynamics of relapse response. This confirms the clinical observation that certain drugs may be overall more successful in lowering the rate of relapses more significantly than others, notwithstanding the fact that patients behave differently across experiments. (c) 2022 Elsevier Ltd. All rights reserved.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Correlates and trajectories of relapses in relapsing-remitting multiple sclerosis
    Young, Carolyn A.
    Rog, David J.
    Sharrack, Basil
    Tanasescu, Radu
    Kalra, Seema
    Harrower, Timothy
    Tennant, Alan
    Mills, Roger J.
    NEUROLOGICAL SCIENCES, 2024, 45 (05) : 2181 - 2189
  • [2] Predictive value of lesions for relapses in relapsing-remitting multiple sclerosis
    Koziol, JA
    Wagner, S
    Sobel, DF
    Slivka, LS
    Romine, JS
    Sipe, JC
    Adams, HP
    AMERICAN JOURNAL OF NEURORADIOLOGY, 2001, 22 (02) : 284 - 291
  • [3] Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis
    Young, P. J.
    Lederer, C.
    Eder, K.
    Daumer, M.
    Neiss, A.
    Polman, C.
    Kappos, L.
    NEUROLOGY, 2006, 67 (05) : 804 - 808
  • [4] Daclizumab for the treatment of relapsing-remitting multiple sclerosis
    Herwerth, Marina
    Hemmer, Bernhard
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (06) : 747 - 753
  • [5] Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Fox, Edward J.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (12) : 1789 - 1797
  • [6] Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
    Hersh, Carrie M.
    Cohen, Jeffrey A.
    IMMUNOTHERAPY, 2014, 6 (03) : 249 - 259
  • [7] Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    Menge, Til
    Dubey, Divyanshu
    Warnke, Clemens
    Hartung, Hans-Peter
    Stuve, Olaf
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1131 - 1139
  • [8] Considerations in the treatment of relapsing-remitting multiple sclerosis
    Calabresi, PA
    NEUROLOGY, 2002, 58 (08) : S10 - S22
  • [9] Teriflunomide for the treatment of relapsing-remitting multiple sclerosis
    Miller, Aaron E.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (02) : 181 - 194
  • [10] Ponesimod for the treatment of relapsing-remitting multiple sclerosis
    Gaber, Tarek A-Z K.
    Eltemamy, Marwa
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2022, 26 (02) : 18 - 19